What the research found

Six major medical organizations publish guidance on menopause hormone therapy in the U.S. and internationally—including the American College of Obstetricians and Gynecologists (ACOG), The Menopause Society, the Endocrine Society, the U.S. Preventive Services Task Force, the International Menopause Society, and the UK's NICE. These guidelines were written between 2013 and 2025 using different methodologies, different evidence reviews, and different criteria for who qualifies for treatment. None supersedes the others, and menopause is not a recognized subspecialty in obstetrics and gynecology, meaning clinicians can complete full training without ever being required to read more than one guideline.

The result is substantial disagreement on key clinical questions. For timing of hormone therapy, most organizations cite an "under 60, or within 10 years of final period" window—but NICE (updated November 2024) bases decisions on symptoms and informed choice with no age cutoff, and ACOG's actual clinical practice guidelines don't formally adopt the age window at all (it appears mainly on patient-facing FAQs). On duration of therapy, ACOG's own documents contradict each other: one recommends "lowest effective dose for shortest duration" (Level A evidence), while another says continuation should be individualized based on symptoms regardless of age (Level C). Organizations like the Menopause Society and NICE have moved toward more flexible language, explicitly opposing arbitrary stopping ages. On testosterone for women, only hypoactive sexual desire disorder after proper diagnosis has broad consensus support, yet ACOG permits a "can be considered" approach for other indications, and no FDA-approved female testosterone formulation exists in the U.S. despite regulatory approval in other countries.

Why it matters for you

If you're tracking hormone levels and considering or using menopause hormone therapy, the guideline fragmentation directly affects what your clinician recommends. The "10-year window" you've heard about may or may not appear in your doctor's actual reference document—it might be their interpretation of informal consensus rather than binding guidance. Similarly, if you've been told to stop therapy at a specific age (often 65), that may reflect ACOG's "shortest duration" language rather than its own weaker recommendation to individualize based on symptoms. When you see your biomarkers improve—energy, sleep quality, lipid profiles, bone density markers—and your clinician suggests stopping anyway because of an arbitrary age threshold, you're experiencing a guideline gap.

For women using testosterone to address sexual dysfunction, libido metrics, or other goals, the landscape is even murkier. Most guidelines agree it's only evidence-supported for diagnosed hypoactive sexual desire disorder, yet off-label use is common because no regulated female formulation exists. Tracking testosterone levels and sexual function outcomes in an app doesn't change the regulatory or guideline reality, but it does create a record of what actually improved for you—which can inform a conversation with a clinician willing to consider the higher-evidence guidance from NICE or the International Menopause Society.

Caveats

  • This is a mapping of published guideline disagreement, not new research on hormone therapy efficacy or safety
  • No studies of clinical outcomes are discussed; the variation reflects methodological and philosophical differences between organizations, not new data
  • The author's observation about arbitrary stopping at age 65 is anecdotal from her own practice, not a published epidemiological finding
  • Guideline recommendations vary in evidence grade (Level A vs. Level C), but the source does not evaluate which is more scientifically sound—only that they coexist in the same organization's documents
  • Regulatory status (FDA approval) is a legal/administrative constraint, not evidence of safety or efficacy